Haplomics, Inc. and Morehouse School of Medicine Announce Translational Research Collaboration Aimed at Developing Innovative Solutions to Address Disparate Outcomes in Hemophilia A
Collaboration Marshalls New Insights and Proprietary Approaches to Address a Serious Complication of Hemophilia Care Experienced by African American Patients
ATLANTA, October 30, 2013 – Atlanta based Haplomics, Inc. a recently established biotech company, and Morehouse School of Medicine (MSM), today announced the signing of a Collaborative Research and Development Agreement. The agreement formalizes an exciting joint effort directed toward eliminating a long-standing and health threatening complication of hemophilia A therapy-the abrupt development of anti-FVIII antibodies.
Hemophilia is a genetic disease that impacts about 1:5000 males worldwide. There are about 450,000 people with hemophilia, but only about 125,000 receive treatment. Since the genetic defect resides on the X chromosome, the overwhelming majority of individuals with hemophilia are male. The genetic defect results in the lack of effective activity of a protein needed to stop bleeding. Major progress has been made in treating hemophilia over the past several decades. In the developed world, young boys diagnosed with hemophilia usually have access to specialized care at a Hemophilia Treatment Center or HTC. The mainstay treatment for hemophilia is the administration of a functional replacement coagulation protein. Previously this treatment was usually given to arrest a bleed in progress. In recent years, many patients with hemophilia are given replacement factor often enough to prevent most bleeds. For many patients this first line therapy, replacement factor, is safe and effective. Indeed with patient compliance and competent care, hemophilia patients who respond well to replacement factor therapy can expect to enjoy a healthy lifestyle, comparable to individuals without the disease.
Regrettably, many patients with hemophilia experience a life and limb threatening side effect after receiving a normal course of factor replacement therapy. These individuals essentially reject the replacement factor and make anti-factor antibodies. This serious adverse response happens to about 20% of all boys of Caucasian ancestry with hemophilia A; but occurs at a rate of about 50% among young boys of African American descent.
Haplomics, Inc. and Morehouse School of Medicine are dedicated to bringing technologies to the clinic that will reduce the development of clotting factor antibodies, allow all hemophilia A patients to benefit from the best available therapies.
Haplomics, Inc. is a biotechnology company developing innovative: (i) diagnostics and predictive systems to assess risk for adverse immune responses to replacement FVIII clotting factor and to guide therapy; (ii) approaches for pre-empting or abating an adverse immune response to a particular biologic, tissue or cell therapy; (iii) biologics offering reduced immunogenicity and antigenicity; and (iv) viral free gene therapy to induce tolerance to FVIII therapy and ultimately make a genetic repair of a patients mutant clotting gene to permit their sufficient production of FVIII to eliminate the need for infusion of outside replacement factor. More information about Haplomics may be viewed at www.haplomicsinc.com.
President and CEO
About Morehouse School of Medicine (MSM)
Morehouse School of Medicine (MSM), located in Atlanta, Ga., was founded in 1975 as the Medical Education Program at Morehouse College. In 1981, MSM became an independently chartered institution. MSM is among the nation’s leading educators of primary care physicians and was recently recognized as the top institution among U.S. medical schools for our social mission. Its faculty and alumni are noted in their fields for excellence in teaching, research and public policy.
James W. Lillard, Jr., PhD, MBA
Associate Dean for Research Affairs
Director, Office for Translational Technologies